WO2024028794 - METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS
National phase entry is expected:
Publication Number
WO/2024/028794
Publication Date
08.02.2024
International Application No.
PCT/IB2023/057843
International Filing Date
02.08.2023
Title **
[English]
METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS
[French]
MÉTHODES DE TRAITEMENT DE TROUBLES DE L'ENDOMÈTRE ET DE L'HYPERPROLIFÉRATION OVARIENNE
Applicants **
TEMPLE THERAPEUTICS BV
Inventors
SAED, Ghassan
Priority Data
63/394,445
02.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6606 | |
| EPO | Filing, Examination, Granting | 178074 | |
| Japan | Filing, Examination, Granting | 5179 | |
| South Korea | Filing, Examination, Granting | 11205 | |
| USA | Filing, Examination, Granting | 37190 |
Total:
238,254
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure provides for methods and compositions that target the interaction of αV/β1 integrin and monomeric MPO in ovarian cancer and other hyperproliferative disorders. Accordingly, aspects of the disclosure relate to a method for treating endometrial or ovarian hyperproliferative disorders in a subject, the method comprising administration of an inhibitor of αV/β1 integrin, an MPO inhibitor, and/or the combination of an αV/β1 integrin and an MPO inhibitor to the subject. In some aspects, the hyperproliferative disorder comprises ovarian cancer or epithelial ovarian cancer. In some aspects, the hyperproliferative disorder comprises endometriosis.[French]
L'invention concerne des méthodes et des compositions qui ciblent l'interaction de l'intégrine αV/β1 et de la MPO monomère dans le cancer de l'ovaire et d'autres troubles hyperprolifératifs. En conséquence, des aspects de l'invention concernent une méthode de traitement de troubles de l'endomètre ou de l'hyperprolifération ovarienne chez un sujet, la méthode comprenant l'administration d'un inhibiteur d'intégrine αV/β1, d'un inhibiteur de MPO, et/ou de la combinaison d'une intégrine αV/β1 et d'un inhibiteur de MPO au sujet. Dans certains aspects, le trouble hyperprolifératif comprend le cancer de l'ovaire ou le cancer de l'ovaire épithélial. Dans certains aspects, le trouble hyperprolifératif comprend l'endométriose.